



Q3C(R6) Impurities: Guideline for Residual Solvents

PDE for Triethylamine and Methylisobutylketone

17 January 2017

International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use



ICH Q3C(R6)

Legal Notice

- This presentation is protected by copyright and may be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

Outline

- Background and Objectives
- Triethylamine
 - Toxicological data
 - Proposed PDE
- Methylisobutylketone
 - Toxicological data
 - Proposed PDE
- Conclusions

Background –Q3C Maintenance

- ICH Q3C core guidance reached *Step 5* in 1997.
- In 1999 a maintenance agreement was instituted and a Maintenance Expert Working Group (EWG) was formed.
- The agreement provided for the re-visitation of solvent Permitted Daily Exposure (PDE) and allowed for minor **changes** to the guidance that included the **existing PDEs**.
- It was also agreed that **new solvents** and PDEs could be **added** based upon adequate toxicity data.

Objectives of current maintenance process

A Maintenance process has been proposed in 2014

1. To add a **new solvent** to the guideline, **Triethylamine**
2. To **revise** the existing **PDE** of the solvent **Methylisobutylketone**, as new toxicological data for this solvent become available

Triethylamine (TEA)

- EWG's review of available toxicity data with TEA:
 - Genotoxicity: limited data, no evidence for genotoxicity
 - Carcinogenicity: no data available
 - Reproductive toxicity: no robust studies for PDE calculation
 - Repeated dose toxicity: rat sub-chronic inhalation study; No-observed-effect-level (NOEL) considered appropriate for PDE calculation;
 - Due to study deficiencies other published animal toxicity data were disregarded from determining a PDE

TEA: PDE calculation*

*see Q3C guideline for details of PDE calculation

- Rat sub-chronic (28 weeks) inhalation study
 - No treatment related effects at all dose groups
 - NOEL of 247 ppm (highest dose) used for PDE
 - PDE = 62.5 mg/day
- Since the PDE is greater than 50mg/day TEA is placed into Class 3 (“solvents with low toxic potential“)

Methylisobutylketone (MIBK)

- MIBK is listed in the Q3C core guideline of 1997 in Class 3 (= solvent with low toxic potential)
- Review of toxicity data available at that time resulted in a PDE of 100 mg/day
- Due to new data from US National Toxicology Program (NTP) 2-year rodent carcinogenicity studies the existing PDE has been revisited

MIBK: New NTP data

- MIBK has been studied by NTP in 2-year rat and mouse inhalation studies
- Primary targets of MIBK toxicity and carcinogenicity were the kidney in rats and the liver in mice
- NTP's conclusion: "some evidence" of carcinogenic activity in rats and mice
- The International Agency for Research on Cancer IARC classified MIBK as a group 2B carcinogen ("possibly carcinogenic to humans")

MIBK: PDE calculation*

*see Q3C guideline for details of PDE calculation

- Rat carcinogenicity data: two different scenarios for PDE calculation
 1. Tumor findings not relevant to humans (rat specific mode of action); PDE calculated for chronic progressive nephropathy in females (Lowest-observed-effect-level LOEL = 450 ppm);
PDE = 45 mg/day
 2. Relevance of tumor findings to humans cannot be excluded; NOEL of 900 ppm is used for PDE calculation;
PDE = 45 mg/day

MIBK: PDE calculation*

*see Q3C guideline for details of PDE calculation

- In mouse study MIBK increased incidence of hepatocellular adenoma/carcinoma in females and males at highest dose (1800 ppm)
 - There is clear evidence of a constitutive androstane receptor (CAR)-mediated mode of action (MOA) for the mouse liver tumors.
 - This MOA is not relevant for humans; therefore no PDE calculation was done based on mouse tumor data.

New PDE value for MIBK

- The former PDE of MIBK was 100 mg/kg and the solvent was placed in Class 3.
- The newly calculated PDE is based upon the NOEL for tumors in male and female rats and the LOEL for chronic progressive nephropathy in female rats from 2-year inhalation study.
- In both cases a PDE of 45 mg/day was calculated.
- Therefore, MIBK is placed into Class 2.

Conclusion (1)

- A Q3C Maintenance process has been initiated to add a new solvent TEA and revise the PDE of MIBK.
- The proposed PDE for TEA is 62.5 mg/day; TEA is placed into Class 3.
- The proposed PDE for MIBK is 45 mg/day; MIBK is placed into Class 2.
- Both PDE values have been adopted by the Assembly under Step 4 on November 9, 2016.

Conclusion (2)

- The PDE for TEA and MIBK document has been integrated as part V in the core Q3C(R5) Guideline which was then renamed Q3C(R6).
- The Table 2, Table 3 and Appendix 1 have been updated to reflect the revision of the PDE for TEA and MIBK.



Thank You!

International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use